Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

The purpose of this study was to investigate the prognostic significance of K-ras mutations in circulating DNA in advanced non-small lung cancer (NSCLC) patients. Serum samples were assessed prior to platinum-based chemotherapy start in 67 patients with advanced NSCLC (stage IIIB or IV), treated bet...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Vol. 50; no. 3; pp. 339 - 346
Main Authors: Camps, Carlos, Sirera, Rafael, Bremnes, Roy, Blasco, Ana, Sancho, Eva, Bayo, Pilar, Safont, Maria Jose, Sánchez, José Javier, Tarón, Miquel, Rosell, Rafael
Format: Journal Article
Language:English
Published: Shannon Elsevier Ireland Ltd 01.12.2005
Elsevier Science
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Codon
Data Interpretation, Statistical
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
Female
Gene Amplification
Genes, ras
Genotype
Humans
K-ras
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Male
Medical sciences
Middle Aged
Molecular markers
Non-small cell lung cancer
NSCLC
Pneumology
Point Mutation
Prognosis
Prognostic factors
Sensitivity and Specificity
Survival Analysis
Tumors of the respiratory system and mediastinum
Molecular markers
NSCLC
K-ras
Prognostic factors
Non-small cell lung cancer
Human
Lung disease
Prognosis
Respiratory disease
Lung cancer
Non-small celt lung cancer
Malignant tumor
Molecular marker
non-small cell lung carcinoma
Point mutation
Bronchus disease
Serum
Onc gene
Non small cell carcinoma
ISSN:0169-5002, 1872-8332
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to investigate the prognostic significance of K-ras mutations in circulating DNA in advanced non-small lung cancer (NSCLC) patients. Serum samples were assessed prior to platinum-based chemotherapy start in 67 patients with advanced NSCLC (stage IIIB or IV), treated between April 1999 and June 2002. Patients were not previously treated with chemotherapy. K-ras oncogene mutations at codon 12 were analyzed by genomic amplification and direct sequencing of the patient's DNA present in serum. Pre-treatment serum was available in all 67 patients. Twenty patients (30%) demonstrated K-ras mutations while 47 patients (70%) had wild-type K-ras. Among K-ras mutations, the amino acid glycine was substituted by cystein in 90% and valine in 10%. When patients were grouped according to K-ras genotype, there was no significant difference for any of the baseline patient characteristics. There was a tendency towards a higher response rate for patients with K-ras mutations versus wild-type K-ras in serum, however not statistically significant ( p = 0.37). Median progression-free survival was 7.3 months versus 5.5 months in patients with mutations and with wild-type K-ras, respectively ( p = 0.23). For median overall survival time, the mutation group was comparable to the wild-type K-ras group with 12.5 and 11.4 months, respectively ( p = 0.28). In conclusion, there were no significant differences between the patients with K-ras mutations and those with wild-type genotype with respect to baseline patient characteristics, response rates, progression-free survival, or overall survival.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2005.06.007